Search
Phenyltoloxamine
go.drugbank.com/drugs/DB11160ApprovedIt is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.
Mixtures: Dologesic DF, Sinutab Sa TabNalidixic acid
go.drugbank.com/drugs/DB00779ApprovedWithdrawnNalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. … Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.
Products: PRAVASTATIN 1A PHARMA 10MG, PRAVASTATIN 1A PHARMA 20MGAmikacin
go.drugbank.com/drugs/DB00479ApprovedInvestigationalVet approvedof patients with the disease who do not respond to traditional treatment. … Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexSynonyms: D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-N(SUP 1)-(4-AMINO-2-HYDROXY-1-OXOBUTYL)-2-DEOXY-, (S)-, -D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINERifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … Product which allowed it to have a status a priority review.
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalA pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. … This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct.
Mixtures: PLENACOR D, Aa-amilzideDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalCilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. … [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]
Mixtures: IMIPENEM/CILASTATINA POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, ARZOMEBA PISA 500MG/500MG (IMIPENEM+CILASTATINA) POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLESodium carbonate
go.drugbank.com/drugs/DB09460ApprovedWithdrawnAs a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.
Mixtures: Sel De Perou, SAL DE FRUTAS PHILLIPS DOBLE ACCION